Chugai Pharmaceutical (4519) Foundayo (orforglipron) prescription trends (IQVIA), Week 11 (week of June 15)

Research evidence excerpt

Chugai Pharmaceutical (4519) Foundayo (orforglipron) prescription trends (IQVIA), Week 11 (week of June 15)

J P M O R G A N Asia Pacific Equity Research

26 June 2026

Chugai Pharmaceutical (4519) Overweight

4519.T, 4519 JP

Foundayo (orforglipron) prescription trends (IQVIA), Price (26 Jun 26):¥7,434

Week 11 (week of June 15) Price Target (Dec-26):¥11,000

On the 26th, IQVIA released Week 11 prescription data (week of June 15) for Japan Equity Research

Foundayo. IQVIA reported 20,594 prescriptions (-5% WoW). While the total

Biotechnology & Pharmaceuticals/

weekly prescription count was below that of the prior week, we believe this reflects Medical Technologies & Services

the impact of June 19 being a holiday (Juneteenth). On a per-business-day basis, AC Seiji Wakao, Ph.D.

however, the average number of prescriptions (Figure 3) was the highest to date,

(81-3) 6736-8612

suggesting that underlying demand momentum is accelerating further. We expect seiji.wakao@jpmorgan.com

additional acceleration as Medicare coverage begins in July. Yugo R. Kamimura, Ph.D.

(81-3) 6736-8635

Eli Lilly announced details of the Medicare GLP-1 Bridge program starting July yugo.kamimura@jpmorgan.com

1. Eligible patients will be able to access Foundayo for $50 per month, and Eli Lilly Naoko Saito

estimates that roughly 20 million Medicare patients could qualify. We will watch (81-3) 6736-8693

this as a measure that could support expanded prescriptions among older obese naoko.saito@jpmorgan.com

patients, a group that previously had limited access. JPMorgan Securities Japan Co., Ltd.

Figure 1: Foundayo and Wegovy Pill: Number of TRx (IQVIA) Figure 2: Foundayo: Number of TRx (LHS) and WoW growth (RHS)

Number of TRx Number of TRx

100,000 86,355 25,000 180%

21,648

90,000 82,062 19,879 20,594 160% 76,620